Michael MilosevicMD, FRCPC
Professor

Contact Info

T. (416) 946-2932
F. (416) 946-2227

Location

Princess Margaret Cancer Centre
610 University Avenue
Toronto
ON, M5G 2M9

Clinical Interests

Gynecologic tumors, Genitourinary tumors

Accepting

Please contact Faculty Member for more information

Degree/Qualifications

BASc, Engineering and Management, University of Waterloo
MD, Queen’s University
FRCPC, Radiation Oncology

Appointments

UT-DRO Vice Chair, Research
Professor, Department of Radiation Oncology, University of Toronto
Associate Director, Radiation Medicine Program, Princess Margaret Hospital/University Health Network, Toronto
Gynecologic cancer site leader, Radiation Medicine Program, Princess Margaret Hospital/University Health Network, Toronto
Director of Research, Radiation Medicine Program, Princess Margaret Hospital/University Health Network, Toronto
Director, STTARR Core III, University Health Network, Toronto
Biomechanical Research Group, Department of Applied Mathematics, University of Waterloo
Chair, Canadian Partnership for Quality Radiotherapy (CPQR)

Research/Teaching

Research Synopsis:

Tumor microenvironment in gynecologic tumors and prostate cancer

 

  • Clinical-translational studies of hypoxia, interstitial fluid pressure (IFP) and tumor metabolism in cervix and prostate cancer. Approximately 600 patients have been accrued to prospective translational studies.
  • Functional and metabolic imaging of human tumors using dynamic CT, dynamic MR and PET
  • Bioluminescence imaging of metabolism in human tumors
  • Pre-clinical and clinical-translational evaluation of the anti-angiogenic drug sorafenib in combination with radiotherapy. Phase I-II studies are currently accruing patients with cervix cancer or renal cell carcinoma. Both studies include extensive evaluation of imaging and tissue-based biomarkers prior to and during treatment.
  • Mathematical modeling of vascularity, interstitial fluid dynamics and treatment response in tumors

 

Adaptive, image-guided radiotherapy for gynecologic tumors

  • Assessment of cervix, uterine and normal tissue motion using 4D-MR imaging
  • Evaluation of online daily imaging techniques for measuring target motion during radiotherapy
  • Development of intensity modulated radiotherapy (IMRT) approaches for treating cervix cancer, including image-guided adaptive radiotherapy with interactive re-planning during fractionated treatment to compensate for changing tumor volume and position
  • Development and implementation of MR-guided brachytherapy for cervix cancer, with treatment optimization in individual patients

 

Publications and Awards

Recent Publications

Lim K, Kelly V, Stewart J, Xie J, Cho Y-B, Moseley J, Fyles A, Lundin A, Rehbinder H, Milosevic M. Pelvic radiotherapy for cervix cancer: Is what you plan actually what you deliver? Int J Radiat Oncol Biol Phys, 74(1), 304-12, 2009.

Zwahlen D, Jezioranski J, Chan P, Haider M, Cho Y-B, Yeung I, Levin W, Manchul Fyles A, Milosevic M. Magnetic resonance image-guided intracavitary brachytherapy for cervix cancer. Int J Radiat Oncol Biol Phys, 74(4), 1157-64. 2009.

Dinniwell R, Chan P, Czarnota G, Haider M, Fyles A, Jaffray D, Milosevic M. Pelvic lymph node topography for radiotherapy treatment planning from contrast-enhanced MR imaging. Int J Radiat Oncol Biol Phys, 74(3), 844-51, 2009.

Stewart J, Lim K, Kelly V, Xie J, Brock K, Moseley J, Cho Y-B, Fyles A, Lundin A, Rehbinder H, Löf J, Jaffray D, Milosevic M. Automated weekly replanning for intensity-modulated radiotherapy of cervix cancer. Int J Radiat Oncol Biol Phys, 2009.

Chopra S, Milosevic M, Haider M, Bristow R, Menard C. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: A pilot study in men with prostate cancer. Int J Radiat Biol, 85(9), 805-13, 2009.

Molavian H, Kohandel M, Milosevic M, Sivaloganathan S. Fingerprint of cell metabolism in the lack of correlation between the interstitial pH and pO2 in solid tumors. Cancer Res, 69(23), 9141-7, 2009.

Back to Top